Sera Prognostics Inc Class A SERA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Sera Prognostics to Present at H.C. Wainwright 26th Annual Global Investment Conference
-
Sera Prognostics to Participate in Panel Discussion at UBS Genomic Medicine Summit on August 14, 2024
-
SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
-
Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024
-
Sera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial
Trading Information
- Previous Close Price
- $7.48
- Day Range
- $7.30–7.67
- 52-Week Range
- $1.56–12.36
- Bid/Ask
- $7.47 / $7.93
- Market Cap
- $249.93 Mil
- Volume/Avg
- 94,985 / 120,295
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2,237.82
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 57
- Website
- https://www.seraprognostics.com
Comparables
Valuation
|
Metric
|
SERA
|
300482
|
688468
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 26.45 | 21.05 |
Price/Book Value | 4.18 | 2.32 | 2.05 |
Price/Sales | 2,237.82 | 4.18 | 6.16 |
Price/Cash Flow | — | 14.74 | 14.42 |
Price/Earnings
SERA
300482
688468
Financial Strength
|
Metric
|
SERA
|
300482
|
688468
|
|---|---|---|---|
Quick Ratio | 2.06 | 5.59 | 4.71 |
Current Ratio | 2.08 | 7.49 | 5.48 |
Interest Coverage | −806.69 | 18.41 | 111.54 |
Quick Ratio
SERA
300482
688468
Profitability
|
Metric
|
SERA
|
300482
|
688468
|
|---|---|---|---|
Return on Assets (Normalized) | −27.67% | 7.29% | 7.46% |
Return on Equity (Normalized) | −36.00% | 9.26% | 9.59% |
Return on Invested Capital (Normalized) | −38.33% | 7.99% | 7.98% |
Return on Assets
SERA
300482
688468
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Zkpyshsk | Vvtdlg | $197.7 Bil | |||
| Stryker Corp
SYK
| Nlcmjkzm | Zrlnz | $135.3 Bil | |||
| Boston Scientific Corp
BSX
| Rydytjn | Nrlqtpv | $124.4 Bil | |||
| Medtronic PLC
MDT
| Zjpsjgv | Xlghb | $114.3 Bil | |||
| Edwards Lifesciences Corp
EW
| Brtkhxfhc | Jyyqly | $39.2 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Zxrt | Ptp | $30.2 Bil | |||
| DexCom Inc
DXCM
| Gcnnxqpkvy | Ftm | $26.9 Bil | |||
| Steris PLC
STE
| Pfdgcgr | Xdpdx | $23.1 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Rxqtfchls | Ybjs | $21.5 Bil | |||
| Insulet Corp
PODD
| Bdlqtgyzh | Qgvdcb | $16.3 Bil |
United States